Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

HMGA1 has predictive value in response to chemotherapy in gastric cancer

Pádua, Diana ; Pinto, Débora Filipa ; Figueira, Paula ; Pereira, Carlos Filipe LU orcid ; Almeida, Raquel and Mesquita, Patrícia (2022) In Current Oncology 29(1). p.56-67
Abstract

Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with... (More)

Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with clinicopathological and treatment data. In this series, HMGA1 expression showed no significant relevance as a prognostic biomarker. Nevertheless, a significantly better overall survival was observed in cases with high levels of HMGA1 when they were treated with chemotherapy, compared to the nontreated ones, implying that they can benefit more from treatment than patients with low expression of HMGA1. We thereby show for the first time that HMGA1 expression has a substantial value as a biomarker of response to chemotherapy in gastric cancer.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Chemotherapy, Gastric cancer, HMGA1, Predictive value, Prognosis
in
Current Oncology
volume
29
issue
1
pages
12 pages
publisher
MDPI AG
external identifiers
  • scopus:85121629926
  • pmid:35049679
ISSN
1718-7729
DOI
10.3390/curroncol29010005
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
id
6e7c09f0-6aa3-4657-a7ab-031d7926e429
date added to LUP
2022-04-12 15:51:23
date last changed
2024-06-17 00:24:35
@article{6e7c09f0-6aa3-4657-a7ab-031d7926e429,
  abstract     = {{<p>Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with clinicopathological and treatment data. In this series, HMGA1 expression showed no significant relevance as a prognostic biomarker. Nevertheless, a significantly better overall survival was observed in cases with high levels of HMGA1 when they were treated with chemotherapy, compared to the nontreated ones, implying that they can benefit more from treatment than patients with low expression of HMGA1. We thereby show for the first time that HMGA1 expression has a substantial value as a biomarker of response to chemotherapy in gastric cancer.</p>}},
  author       = {{Pádua, Diana and Pinto, Débora Filipa and Figueira, Paula and Pereira, Carlos Filipe and Almeida, Raquel and Mesquita, Patrícia}},
  issn         = {{1718-7729}},
  keywords     = {{Chemotherapy; Gastric cancer; HMGA1; Predictive value; Prognosis}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{56--67}},
  publisher    = {{MDPI AG}},
  series       = {{Current Oncology}},
  title        = {{HMGA1 has predictive value in response to chemotherapy in gastric cancer}},
  url          = {{http://dx.doi.org/10.3390/curroncol29010005}},
  doi          = {{10.3390/curroncol29010005}},
  volume       = {{29}},
  year         = {{2022}},
}